# Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

> **NCT04083963** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 13 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04083963
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-09
- **Primary completion:** 2026-09-27
- **Final completion:** 2026-09-27
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04083963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04083963, "Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04083963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*